Statement on Report of the Long-Term Care Homes Public Inquiry
TORONTO, July 31, 2019 /CNW/ - Earlier today, The Honourable Justice Eileen Gillese released the final report of the Long-Term Care Homes Public Inquiry, including a series of recommendations directed to the Ministry of Long-Term Care, the Office of the Chief Coroner, the College of Nurses, and the operators of long-term care homes.
"The Ontario Long Term Care Association would like to thank Justice Gillese and her team for their two years of dedication to the work of this Inquiry," said Donna Duncan, CEO of the Association. "We would also like to acknowledge the fortitude of the families throughout this difficult time."
"The Association will be carefully reviewing Commissioner Gillese's thorough and thoughtful report over the coming weeks and months, and looks forward to working with all of our long-term care sector partners, including the Ministry of Long-Term Care, to advance the Inquiry's recommendations," Duncan said.
"Long-term care staff and operators are dedicated to providing safe and caring environments for the people who live in their homes," she added. "The Inquiry has been a difficult but important process that will further strengthen homes' ability to provide safe, caring, and high-quality care."
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030
The global market for Laboratory...
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...
During an awards ceremony to present the 2024 list of Best Workplacestm in Canada, Great Place to Work® announced the 50 Best Workplacestm in Canada with 100-999 employees....
